Clinical Trial Update: A Long Term Safety Study of Apricitabine in HIV-infected Patients [Phase 3]

View source ↗

Summary

A Phase 3 long-term safety study of apricitabine in HIV-infected patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Apricitabine (Apricitabine)

Snippet

Sponsor: Avexa | Conditions: HIV Infections | Phase 3 | Status: WITHDRAWN